1. Long-term relapse-free survival enabled by integrating targeted antibacteria in antitumor treatment.
- Author
-
Wang Y, Han Y, Yang C, Bai T, Zhang C, Wang Z, Sun Y, Hu Y, Besenbacher F, Chen C, and Yu M
- Subjects
- Female, Male, Humans, Animals, Mice, Breast Neoplasms immunology, Breast Neoplasms drug therapy, Breast Neoplasms therapy, Breast Neoplasms pathology, Cell Line, Tumor, Prostatic Neoplasms immunology, Prostatic Neoplasms therapy, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Microbiota drug effects, Silver chemistry, Disease-Free Survival, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Neoplasm Recurrence, Local immunology, Tumor Microenvironment immunology, Tumor Microenvironment drug effects
- Abstract
The role of tumor-resident intracellular microbiota (TRIM) in carcinogenesis has sparked enormous interest. Nevertheless, the impact of TRIM-targeted antibacteria on tumor inhibition and immune regulation in the tumor microenvironment (TME) remains unexplored. Herein, we report long-term relapse-free survival by coordinating antibacteria with antitumor treatment, addressing the aggravated immunosuppression and tumor overgrowth induced by TRIM using breast and prostate cancer models. Combining Ag
+ release with a Fenton-like reaction and photothermal conversion, simultaneous bacteria killing and multimodal antitumor therapy are enabled by a single agent. Free of immune-stimulating drugs, the agent restores antitumor immune surveillance and activates immunological responses. Secondary inoculation and distal tumor analysis confirm lasting immunological memory and systemic immune responses. A relapse-free survival of >700 days is achieved. This work unravels the crucial role of TRIM-targeted antibacteria in tumor inhibition and unlocks an unconventional route for immune regulation in TME and a complete cure for cancer., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF